论文部分内容阅读
目的探讨Ⅱ、Ⅲ和Ⅳ期非小细胞肺癌(NSCLC)患者外周血及其肿瘤组织中核糖核苷酸还原酶M1(RRM1)mRNA表达水平是否有一致性及其与吉西他滨化疗疗效之间关系。方法病例组为49例接受吉西他滨化疗的NSCLC患者,收集化疗前、化疗一疗程后、病情恶化或停止治疗前外周血及应用吉西他滨化疗前的病理组织蜡块,对照组为同期12例健康体检者。应用荧光定量PCR法检测RRM1 mRNA表达水平。结果病例组中,RRM1在外周血单个核细胞中的表达与在病理组织中的表达无差异(P=0.336),外周血单个核细胞中的表达水平在化疗前与化疗一疗程后无统计学差异(P=0.936),化疗前与化疗结束或病情恶化后亦无统计学差异(P=0.878)。应用吉西他滨化疗4个周期后,RRM1 mRNA低水平表达组(n=30)和高水平表达组(n=19)有效率分别为76.7%和21.1%(P<0.05)。结论检测NSCLC患者外周血RRM1 mRNA是一种简便、快捷的方法,可以替代必须检测病理组织的传统方法,减轻患者痛苦及经济负担。
Objective To investigate whether there is consistency in the expression of ribonucleotide reductase M1 (RRM1) mRNA in peripheral blood and its tumor tissues in patients with stage II, III, and IV non-small cell lung cancer (NSCLC) and its relationship with gemcitabine chemotherapy. Methods A total of 49 patients with NSCLC who received gemcitabine chemotherapy were enrolled in this study. The pathological tissue blocks of peripheral blood and prior to gemcitabine chemotherapy were collected before chemotherapy, after one course of chemotherapy, before the deterioration of the disease, or before treatment was stopped. The control group was 12 healthy subjects during the same period. . Real-time quantitative PCR was used to detect the expression of RRM1 mRNA. Results In the case group, the expression of RRM1 in peripheral blood mononuclear cells was not different from that in pathological tissues (P=0.336). The expression level of RRM1 in peripheral blood mononuclear cells was not statistically significant before and after chemotherapy. The difference (P=0.936) was not statistically different before chemotherapy and after the end of chemotherapy or worsening of disease (P=0.878). After 4 cycles of gemcitabine chemotherapy, the effective rates of low-level RRM1 mRNA expression group (n=30) and high-level expression group (n=19) were 76.7% and 21.1%, respectively (P<0.05). Conclusion The detection of RRM1 mRNA in peripheral blood of patients with NSCLC is a simple and rapid method, which can replace the traditional method of detecting pathological tissue, and reduce the suffering and economic burden of patients.